Comparative Pharmacology
Head-to-head clinical analysis: PONLIMSI versus QINLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONLIMSI versus QINLOCK.
PONLIMSI vs QINLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) kinase signaling. It binds to both the switch pocket and the activation loop of KIT and PDGFRA, preventing kinase activation and inhibiting downstream signaling pathways involved in tumor cell proliferation and survival.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
150 mg orally once daily with food, until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Terminal elimination half-life is approximately 15 hours (range 11–20 hours) in patients with advanced GIST. This supports twice-daily dosing.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 80% of the administered dose, with renal excretion of unchanged drug being minimal (<1%).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor